ProCE Banner Activity

CE / CME

Moving Toward Improved Outcomes in Triple-Negative Breast Cancer

Interactive Video Lecture

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is particularly common among Black women. The treatment landscape for TNBC has recently grown to include immune checkpoint inhibitors and the antibody–drug conjugate sacituzumab govitecan—novel agents associated with both substantial benefit and challenging toxicities. This activity provides expert advice on how oncology/hematology APPs can integrate these new agents into practice, including recommendations on patient education, monitoring, managing toxicities, and overcoming healthcare disparities.

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: March 08, 2022

Expiration: March 07, 2023

Begin Activity

Share

Faculty

Stephanie Andrews

Stephanie Andrews, MS, APRN-C

Nurse Practitioner
Department of Malignant Hematology
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Sara A. Hurvitz

Sara A. Hurvitz, MD

Professor of Medicine
Director
Breast Cancer Clinical Trials Program
Division of Hematology/Oncology
David Geffen School of Medicine
Medical Director
Clinical Research Unit
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California

Filipa Lynce

Filipa Lynce, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Breast Medical Oncologist
Division of Breast Oncology
Dana Farber Cancer Institute
Boston, Massachusetts

Acknowledgement

This program is cosupported by educational grants from Gilead Sciences, Inc. and Seagen Inc.

This activity is supported by an educational grant from Gilead Sciences, Inc.

Provided by

ProCE Banner

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize healthcare disparities in breast cancer and their potential impact on treatment and outcomes

  • Describe the role of novel agents in the treatment of TNBC

  • Identify potential toxicities of novel therapies for TNBC and appropriate management steps

  • Incorporate current recommendations for cancer treatment during the COVID-19 pandemic, including COVID-19 vaccinations

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Ms Andrews: fees for non-CME/CE services: Genentech.

Dr Hurvitz: contracted research: Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, Cytomx, Daiichi Sankyo, Dignitana, Eli Lilly, Genentech/Roche, Gilead, GlaxoSmithKline, Immunomedics, Macrogenics, Novartis, Pfizer, OBI Pharma, Phoenix Molecular Designs, Ltd, Pieris, Puma Biotechnology, Radius, Sanofi, Seagen, Zymeworks.

Dr Lynce: consulting fees: AstraZeneca, Bristol-Meyers Squibb, Daiichi Sankyo, Pfizer.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

CME Info

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete the evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: March 8, 2022
Expiration date: March 7, 2023

Format

Interactive video lecture

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until March 7, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.